Jubilant Pharmova targets revenue doubling by 2030

Jubilant Pharmova aims to double its revenue by FY30 to Rs. 13,500 crore from Rs. 6,703 crore in FY24, with an EBITDA margin target of 23% to 25% by FY30. Current trailing 12-month revenue is Rs. 7,404 crore, with an EBITDA margin of 17%.

The company plans to achieve this through leadership in radiopharma, strengthening its position in allergy immunotherapy, doubling capacity for CDMO sterile injectables in Spokane, US, adding large pharma customers for CRDMO, and launching new generics products.

Q1 FY26 results showed total income of Rs. 1,913 crore, up 10% year-on-year, and EBITDA of Rs. 302 crore, up 14% year-on-year. Net debt stands at Rs. 1,535 crore as of June 30, 2025.